Navigation Links
UC scientists awarded $1.7 million for low back pain research
Date:1/29/2008

CINCINNATIThe National Institute of Neurological Disorders and Stroke has awarded $1.7 million to University of Cincinnati (UC) anesthesiology researchers to study a condition that costs Americans $50 billion a yearlow back pain.

Back pain is the leading cause of disability in Americans younger than 45 years old and is experienced by 50 to 80 percent of adults at some point in their lives. Back pain becomes chronic if it persists for more than three months and the cause can sometimes be difficult to determine.

The UC researchers are focusing their five-year study on inflammation and how its effects on sensory neurons in the low back cause persistent chronic pain.

The team, led by Jun-Ming Zhang, MD, director of UCs Pain Research Center, believes small molecules called chemokines are key factors in the development of pain. Chemokines are a family of small cytokineschemical messenger molecules used by immune and nerve cells to communicate with other cells.

If we can determine the role these chemokines play in the development of back pain we can hopefully develop better medications to treat the problem, says Zhang.

Zhang says acute (short-term) pain can actually be beneficial. Acute pain responses to potentially dangerous stimulilike the neural circuitry that tells you to pull your hand away from a hot stoveare essential for survival, says Zhang.

But when pain becomes chronic, it serves no useful purpose, he says, and often affects a persons quality of life.

Back pain can be caused by physical trauma such as a sports injury, lifting heavy items or from a car accident, Zhang explains. For others, medical conditions such as a herniated disc cause pain. But many people experience back pain for no apparent reason.

When a patient goes to the doctor for low back pain, they may undergo an MRI or an X-ray. Sometimes these tests show anatomical reasons for the pain such as a herniated disc. But for some patients, tests dont show any physical evidence for why they are experiencing low back pain, he says.

Zhang adds that the lack of physical evidence can be very frustrating for patients and make it more difficult for doctors to help a patient effectively manage their pain through medication and other treatment therapies.

Thats why we hope to identify specific molecules that contribute to low back pain development. Our goal is to develop a non-opiod analgesic targeting those molecules to alleviate pain, says Zhang.

In previous research, Zhang and his team, including Judith Strong, PhD, co-investigator for the new study, found that pain-sensing neurons can become abnormally sensitive or fire spontaneously in the absence of stimuli. This early spontaneous activity plays a key role in setting up the pathological pain state.

We found that by blocking the early spontaneous activity of an injured nerve we can completely prevent the development of chronic pain. This technique could be extremely useful for combat nerve injuries and amputations that often lead chronic pain, he says.

In the new study, the team will explore how inflammation may contribute to the development of low back pain by intentionally causing this abnormal neuronal firing.


'/>"/>

Contact: Jamie Kaun
jamie.kaun@uc.edu
513-558-4625
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. Scientists explore factors contributing to DNA mutations
2. CIHR news: U of S scientists find plant gene that affects stress resistance
3. Scientists use nanomaterials to localize and control drug delivery
4. Scientists identify genes linked to lupus in women
5. Scripps research scientists find new genetic mutation that halts the development of lupus
6. Jefferson scientists uncover role of cancer stem cell marker: controlling gene expression
7. Jefferson scientists find protein helps pancreatic cancer cells evade immune system and spread
8. 2 Hebrew University scientists awarded Wolf Prizes
9. UCLA scientists restore walking after spinal cord injury
10. Scientists Report Refinements to Brain Surgery
11. Jefferson scientists find protein potential drug target for treatment-resistant prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... ... LLC (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions ... definitive agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an ... an educational webinar, they will present the line of epMotion automated liquid handling ... easy you can automate everyday pipetting tasks. , Ideal for scientists and lab ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Golseth Agency, a Texas based ... area, is spearheading a regional charity campaign organized to provide support to Christina Upchurch ... of this year, Christina and her children returned from out of town to find ...
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the ... efforts with its product now available through Jet.com. , After 25 years of ... powdered drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... 15, 2017 AccuGenomics, Inc., a diagnostic company ... announced that the company has provided an AccuKit to ... Carolina at Chapel Hill and to Qura Therapeutics for ... and quantify HIV reservoir and viral expression in human ... HIV Cure Center is a joint initiative between the ...
(Date:8/8/2017)... Israel, Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), ... today reports its financial results for the second quarter ... during the second quarter 2017 and to date: ... clinical development programs for the Company,s lead project, BL-8040: ... pivotal study with BL-8040 as novel stem cell mobilization ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: